Eurosurveillance banner




Announcements
Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Monthly Release  2001: Volume 6/ Issue 7 Article 1 Printer friendly version
Back to Table of Contents
en es fr it
Next

Eurosurveillance, Volume 6, Issue 7, 01 July 2001
Surveillance report
Confirmed interruption of indigenous measles transmission in Catalonia

Citation style for this article: Salleras L, Domínguez A, Torner N. Confirmed interruption of indigenous measles transmission in Catalonia. Euro Surveill. 2001;6(7):pii=230. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=230
L. Salleras, A. Domínguez, N. Torner
Department of Health and Social Security, Generalitat Catalonia, Barcelona, Spain

From November 1998 to December 2000, 84 suspected measles cases were reported in Catalonia (6 090 040 inhabitants). Of the 73 laboratory tested cases (87%), 20 showed IgM antibodies specific to measles and 3 were epidemiologically linked to a confirmed case. Among these 23 confirmed cases, 13 were indigenous, the last two cases reported dating back from June 1999 and July 2000. These results confirm the success of the measles elimination programme implemented in 1998 in Catalonia.

Background

Measles is a candidate disease for elimination, given that humans are the only hosts of the virus, that subclinical cases are very rare, and that an efficacious vaccine (offering 95% protection) is available (1). As already shown in the United States, the transmission of indigenous measles ceased in 1993, according to data from genetic analysis of isolated measles virus (2-4,15).

In 1988 the Department of Health and Social Security of Catalonia, a region of Spain, started a programme for the elimination of measles in the region by the year 2000 (5-9). The incidence of measles infection in Catalonia (estimated population 6 090 040) declined from 470 per 100 000 inhabitants in 1983 to 1.01/100 000 in 1997 (5) and 0.5/100 000 inhabitants in 1999 (figure 1). In light of this, the public health authorities decided in 1997 to introduce an individualised reporting status for measles (11-13). The individualised report form provides information on clinical features as well as details such as the name, telephone number, and address of a patient, thus allowing a complete epidemiological study of each reported case.

Methods

The final stage of the programme "Elimination of measles in Catalonia by the year 2000)" began in November 1998. Three main strategies were adopted.

a) Improvement of the immunisation status of the susceptible population by giving the second dose of the measles-mumps-rubella (MMR) vaccine at age 4 in the 1999 vaccine calendar instead of at age 11 as was set in 1988, and by a selective plan for administration of the second dose to the cohorts born between 1990 and 1993, to ensure that all children were properly vaccinated (10,14). Vaccine certificates are checked by the public health department to verify the first and second doses of MMR vaccine and to determine coverage of the second dose.

b) Enhanced epidemiological surveillance of suspected cases of the disease, which includes prompt notification of the case by the attending physician (within 24 hours of onset) to the public health department and active follow up of the case and his or her contacts, with concise and exhaustive collection of all epidemiological information relevant to the case. A suspected case would be defined as a patient with clinical features of measles virus infection (rash for more than three days, fever above 38,5°C, cough and/or coryza and/or conjunctivitis) for whom the diagnosis has not yet been confirmed by serological tests or by a relation to a laboratory confirmed case. A laboratory confirmed case would be a suspected case confirmed by specific serological test and/or isolation of measles virus from urine specimens. An epidemiologically confirmed case would be a suspected case related epidemiologically to a laboratory confirmed case of measles.

The epidemiological information collected includes clinical features, immunisation status, travel, school attendance, and any other information that might be useful to determine the source of transmission and probable susceptible contacts.

Blood and urine specimens are collected from the 4th to 11th day after the appearance of the rash either by staff belonging specifically to the programme or by hospital or primary care staff. Laboratory determination of specific IgM type antibodies by an indirect immunofluorescence method is carried out immediately, and the case can thus be confirmed promptly. If positive, the urine specimen is cultured on B95a cells to isolate the virus for genetic analysis (3,4). With regard to its origin, a confirmed case would be considered imported if the patient had been outside Catalonia 7 to 18 days before the onset of the exanthem or had had contact with a suspected case from abroad. A case is defined as indigenous if there is no epidemiological evidence of transmission from a foreign source.

c) Vaccination of the susceptible population who had contact with the case (schoolmates, household contacts) and inquiries to see whether there are unreported cases. Susceptible contacts would be all those younger than 25 years who can not prove they have received two doses of MMR vaccine.

Results are assessed by surveillance of the morbidity during the years in which the programme has been operative, from 1998 to 2000.

Results

Certifications of the second MMR vaccination dose collected from schools and primary care centres showed a registered coverage of 85%.

According to the case definition, the number of suspected cases notified between November 1998 and December 2000 was 84 (figure 2). Clinical specimens were obtained from 73/84 (87%). Only 20 of these had positive IgM antibodies to the measles virus, with 3 more being confirmed by epidemiological relation to a laboratory confirmed case.

From the beginning of the programme on 1st November until 31st December 1998, 10 cases were reported. Only 6 of these could be analysed and were confirmed as negative by laboratory assessment. Of the 49 cases reported from January to December 1999, 44 were analysed and 17 confirmed as positive for to anti-measles IgM antibodies. In addition, one was confirmed by exposure to an outbreak. From January to December 2000, 25 cases were reported of whom 23 were analysed. Only 3 of these cases were confirmed, and 2 more considered confirmed because they were related to a laboratory confirmed case.

Of the cases confirmed in 1999, 6/18 (33%) were proved by epidemiological evidence to be imported. Four (80%) of the five cases confirmed in 2000 were proved to be imported by epidemiological evidence, and one case lives in an urban area where most of the inhabitants are immigrants from Morocco, Pakistan, and the Philippines, which leads us to suspect that this case could also be imported. Thus no indigenous cases were confirmed from June 1999 to July 2000. From July to December 2000 there was only one doubtful case, who was, however, classified as indigenous owing to a lack of evidence of contact with an imported case.

Of all reported cases (with clinical criteria) 87% (73/84) were virologically tested between the 4th and 11th day of the onset of exanthem. Of the tested specimens only 27% (20/73) were confirmed by identification of positive IgM antibodies to measles. The diagnosis of measles was discarded for the remaining 73% (53/73).

Laboratory surveillance of reported cases has markedly improved since the start of the programme (figure 2). The measles virus was isolated from urine in 57% (13/23) of the confirmed cases. Of the 23 confirmed measles cases, 43% (10/23) were imported because they either arrived in

Catalonia within the incubation period or were in contact with some relatives from abroad who were ill; 57% (13/23) were indigenous, with the last two reported and confirmed indigenous cases being in June 1999 and July 2000 (figure 3).

Conclusion

No indigenous cases of measles occurred in Catalonia between June 1999 and July 2000. During the elimination programme for measles, it is crucial to carry out strict active epidemiological surveillance of all reported cases, to confirm them by laboratory data and to stop the transmission of the virus. In the second and third year of the elimination programme, 89.7% (44/49) in 1999 and 92% (23/25) in 2000 were laboratory tested, compared with only 60% (6/10) in the last quarter of 1998. The aim of the programme to undertake laboratory testing of all reported cases has been reached, if we consider those confirmed by epidemiological relation to a laboratory confirmed case (figure 2).

It should be stressed that for all confirmed indigenous cases, their immunisation status with respect to the measles virus was correct according to their age (figure 4). Of the 10 confirmed imported cases, only three had a correct immunisation status for measles according to their age (two were younger than 15 months, and one was 33 years).

Most of the Catalan population at risk of coming into contact with an imported measles case are correctly immunised. It is therefore probable that there will be few or even no confirmed indigenous cases in the future. Furthermore, whenever clinical features lead to a diagnosis of a suspected case of measles – if this is immediately reported and serologically confirmed – it is mandatory to investigate the possibility of foreign contacts. This may be difficult because of the large flow of immigrants currently arriving in Catalonia.

We may conclude that the specific procedures started up in 1998, according to the goal set by the health plan to achieve measles elimination in Catalonia by 31 December 2000, seem to have succeeded and interruption of transmission of indigenous measles virus can be confirmed in our community (16).


References

1. Markowitz LE, Orenstein WA. Measles vaccines. Pediatr Clin North Am 1990; 37: 603-25.

2. Orenstein WA, Markowitz LE, Atkinson WL, Hinman AR. The experience with measles in the United States. In : Kurstak B, ed. Measles and poliomyelitis. Vaccines, immunization and control.Vienna: Springer, 1993 : 25-36.

3. Rota JS, Rota PA, Reed SB, Reed SC, Pattamadilok S, Bellini WJ. Genetic analysis of measles viruses isolated in the United States 1995-1996. J Infect Dis 1998 ; 177: 204-8.

4. Watson JC, Reed SC, Rhodes PH, Hadler SC. The interruption of transmission of indigenous measles in the United States during 1993. Pediatr Infect Dis 1998 ; 17: 363-6.

5. Salleras L, Vidal J, Llorens J; Rodriguez-Hierro F; de la Puente ML, Canela J. Guia per a l’eliminació del xarampió a Catalunya. Barcelona: Departament de Sanitat i Seguretat Social de la Generalitat de Catalunya, 1991.

6. Departament de Sanitat i Seguretat Social de la Generalitat de Catalunya. Document marc per a l’elaboració del Pla de salut de Catalunya. Barcelona, 1991.

7. Departament de Sanitat i Seguretat Social de la Generalitat de Catalunya. Pla de salut de Catalunya 1992-1995. Barcelona, 1992.

8. CDC. Measles eradication. Recommendations from a meeting cosponsored by the World Health Organization, The Pan American Health Organization and CDC. Morb Mortal Wkly Rep Morbidity and Mortality Weekly Report 1997; 46 (R11) : 1-20

9. CDSC. Eliminating measles in Europe by 2007. Commun Dis Rep CDR Wkly 1997; 7: 425-8.

10. Godoy P, Dominguez A, Salleras L. Measles: Effect of two dose vaccination programme in Catalonia. Bull World Health Organ 1999; 77: 132-7.

11. Domínguez A, Carmona G, Martínez A. Estratègies per a l’eliminació del xarampió a Catalunya. Pediatria Catalana 1999; 59: 23-30.

12. Decret 316/1996, de 9 de desembre, pel qual es modifica el procediment de notificació de determinades malalties de declaració obligatòria al Departament de Sanitat i Seguretat Social de la Generalitat de Catalunya. DOGC 1998; 2792: 15801.

13. Decret 395/1996, 12 de setembre, pel qual s’estableixen els procediments de notificació de les malalties de declaració obligatòria i brots epidèmics a l Departament de Sanitat i Seguretat Social de la Generalitat de Catalunya.DOGC 1996; 2299: 12883-12890.

14. Domínguez A, Vidal J, Plans P, Carmona G, Godoy P, Batalla J, et al. Measles immunity and vaccination policy in Catalonia. Vaccine 1999; 17: 530-4.

15. CDC. Goal to eliminate measles from United States. Morb Mortal Wkly Rep Morbidity and Mortality Weekly Report 1978; 27: 391.

16. Salleras Ll, Domínguez A, Vidal J, Torner N. Confirmación de la interrupción de la transmisión del sarampión autóctono en Cataluña. 1999-2000. Vacunas Invest Pract 2001; 2: 5-10



Back to Table of Contents
en es fr it
Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.